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Abstract: Human Ribonuclease 6 is a secreted protein belonging to the ribonuclease A (RNaseA)
superfamily, a vertebrate specific family suggested to arise with an ancestral host defense role.
Tissue distribution analysis revealed its expression in innate cell types, showing abundance in
monocytes and neutrophils. Recent evidence of induction of the protein expression by bacterial
infection suggested an antipathogen function in vivo. In our laboratory, the antimicrobial properties of
the protein have been evaluated against Gram-negative and Gram-positive species and its mechanism
of action was characterized using a membrane model. Interestingly, our results indicate that RNase6,
as previously reported for RNase3, is able to specifically agglutinate Gram-negative bacteria as a main
trait of its antimicrobial activity. Moreover, a side by side comparative analysis with the RN6(1–45)
derived peptide highlights that the antimicrobial activity is mostly retained at the protein N-terminus.
Further work by site directed mutagenesis and structural analysis has identified two residues involved
in the protein antimicrobial action (Trp1 and Ile13) that are essential for the cell agglutination
properties. This is the first structure-functional characterization of RNase6 antimicrobial properties,
supporting its contribution to the infection focus clearance.
Keywords: RNases; host defence; antimicrobial peptides; cell agglutination; infectious diseases
1. Introduction
The RNaseA superfamily is a vertebrate-specific gene family that comprises a wide set of secreted
ribonucleases displaying a variety of biological properties [1,2]. In particular, distant related members
were reported to share innate immunity properties, suggesting that the vertebrate RNases have
evolved as a host-defense family [3–5]. Eight functional members are found in humans, known as the
“canonical RNases” (Figure 1), sharing a common structural fold and catalytic triad [6]. Within the
family, we can differentiate three main phylogenetic lineages (RNase5, RNases2/3 and RNases6–8)
related to host defense [7–10]. The eosinophil ribonucleases, EDN (eosinophil derived neurotoxin,
RNase2) and ECP (eosinophil cationic protein, RNase3), are two secretory ribonucleases stored in
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the secondary granules of eosinophils and released at the focus of infection [11,12]. RNase2 and
3 genes have diverged after gene duplication, accumulating rapidly non-silent mutations through
positive selection pressure [13,14]. RNase2 acts as a potent modulator of the immune host system, and
additionally displays a high antiviral activity against rhinovirus, adenovirus and syncytial respiratory
virus in a RNase catalytic activity dependent manner [15–17]. RNase3 possesses a highly antimicrobial
activity against bacteria [11,18–21], and many parasites, such as helminths and protozoa [22].
By contrast, the antimicrobial properties of RNase3 are not dependent on the ribonuclease activity of the
protein [18,23]. On the other hand, RNase7 is another RNase secreted by a variety of epithelial
tissues [24] and displaying a high antimicrobial activity against a wide range of bacteria, regarded as
a major contributor to the skin barrier protection [25–28]. In turn, RNase6 has been related with the
host immune system protection, being expressed in neutrophils and monocytes and displaying a high
antimicrobial activity [29]. Recently, it has been reported that RNase6 and RNase7 play an important
role in bacterial clearance at the urinary tract [30]. Nonetheless, our understanding of the antimicrobial
mechanism of action of the RNase6 is still poor.
Although the secreted vertebrate RNases share an overall globular three-dimensional prototypical
scaffold, a catalytic triad and a particular disulfide pattern, their amino acid sequence identity ranges
from 30% to 70%. Notwithstanding, despite the low sequence conservation among some RNases
homologues, conserved structural features at the N-terminal region correlated to their host-defense
properties [3]. Comprehensively, some human RNases are endowed with the features present
on antimicrobial proteins and peptides (AMPs), sharing a marked cationicity that facilitates the
electrostatic interaction with the negatively charged bacterial surfaces, abundance of hydrophobic
residues, and the presence of dynamic amphipathic modules that can adopt secondary structures
upon interaction with the bacterial envelopes [7,31]. Amidst the antimicrobial human RNases, despite
their importance in the innate immune system, some members are poorly characterized and their
antimicrobial features are yet to be described [17,28,30,32]. That is the case of the human RNase6, which
is a small cationic protein mainly expressed in neutrophils and monocytes [29]. Interestingly, human
RNase6 has been recently described as a key player in the protection of the urinary tract [30]. In spite
of these encouraging findings, little is known about the antimicrobial mechanism of action of this
RNase during infection.
In this work, we have characterized the antimicrobial mechanism of action of the human RNase 6
at both cell wall and membrane levels by describing its bactericidal effect against Gram-positive and
-negative bacteria using a wide range of biophysical and microscopy approaches. Our results highlight
that the antimicrobial properties of the protein are comparable to its RNase3 homolog and correlate to
the bacterial cell damage and agglutination activities. Additionally, the bactericidal membrane leakage
and bacterial agglutination properties of the protein are largely retained at its N-terminal domain.
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Figure 1. (A) Structure-based sequence of the eight canonical human RNases N-terminal domain
together with RNaseA. The active site residues are highlighted in yellow. RNase6 tested mutations
related to antimicrobial activity are labeled in green. The alignment was performed using ClustalW,
and the picture was drawn using ESPript [33]. Labels are as follows: red box, white character for strict
identity; red character for similarity in a group and character with blue frame for similarity across
groups (red box, white character: strict identity; red character: similarity in a group; red character
with blue frame: similarity across groups; yellow box, black character: catalyst residue); (B) RNase6
(PDB 4X09; [34]) and RNase3 (PDB 4A2O; [35]) three-dimensional structure surface representations
using the CONSURF web server ([36]) featuring the relationships among the evolutionary conservation
of amino acid positions in the RNaseA family. The three-dimensional structure shows residues colored
by their conservation score using the color-coding bar at the image bottom.
2. Results
In order to evaluate the antimicrobial mechanism of action of RNase6, we used different
experimental approaches that combined the analysis of the protein activity in synthetic lipid
bilayers with its action on bacteria cultures. The antimicrobial properties of the protein and its
N-terminus derived peptide were evaluated against Gram-positive and Gram-negative species.
Additionally, we have also evaluated the protein affinity for bacterial cell wall lipopolysaccharides
(LPS). Finally, N-terminus mutant variants were designed and their bactericidal activity and cell
agglutinating properties were compared to the wild-type protein. All the results have been compared
to the previously characterized human RNase3, taken as a positive control [21]. On the other hand,
the family reference protein (RNaseA) did not display any of the tested antimicrobial and membrane
damage activities at the same assayed conditions [37–40].
2.1. Membrane and Cell Wall Interaction
Our first approach to define the antimicrobial mechanism of action of the human RNase6 and its
derived N-terminal peptide RN6(1–45) was performed by the characterization of the interaction at the
membrane and cell wall levels.
By monitoring the intrinsic tryptophan fluorescence signal of the proteins and peptide upon
incubation with phospholipid vesicles and LPS micelles, we were able to record the blue-shift
in the tryptophan spectra, that this residue experiences when is embedded in a hydrophobic
microenvironment. Thus, in order to assess the protein ability to interact with phospholipid bilayers we
registered the intrinsic tryptophan fluorescence signal and the λmax shift in presence of charged (1,2-
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dioleoyl-sn-glycero-3-phosphoglycerol (DOPG)), neutral (1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC)) and mixed (DOPC/DOPG) liposomes (Table 1). The recorded spectrum for both RNases
and the RNase6 derived N-terminal peptide showed no significant blue-shift upon incubation with
non-charged large unilamellar vesicles (LUV). On the other hand, significant λmax shift towards the
blue was experienced when incubated with both charged and mixed LUV. In addition, the two proteins
and the assayed peptide also underwent a blue-shift in their emission spectra in the presence of LPS
micelles, thereby indicating their ability to interact with the negatively charged bacterial cell membrane
and envelope components.
Table 1. Tryptophan fluorescence in the presence of lipid vesicles and LPS micelles for RNase3, RNase6
and RN6(1–45).
Protein/Peptide λmax for Fluorescence Emission (nm)
Buffer DOPC a DOPG a DOPC:DOPG(3:2) a LPS a
RNase3 343 - 3 3 4
RNase6 345 - 2 6 4
RN6(1–45) 343 - 8 9 3
a The shift in the maximum emission wavelength compared with the reference value for buffer sample
is indicated.
To further characterize the interaction of RNase3, RNase6 and RN6(1–45) with the bacterial cell
wall we performed a fluorimetric assay using the BODIPY® cadaverine (BC) probe. Lipopolysaccharide
binding affinity was determined as a result of the competitive displacement of BC, which mimics the
lipid A portion of the LPS. The binding affinities of RNase3, RNase6 and its N-terminal derived
peptide RN6(1–45) for the LPS molecule as a function of the protein concentration were tested.
Their 50% effective dose (ED50) values, defined as the concentration for which half BC displacement
occurs, and the total BC displacement (shown as a percentage) are displayed in Table 2. Both RNases
and the derived peptide displayed a high affinity with the negatively charged LPS molecule, being
able to totally displace the BC molecule at a micromolar range.
Table 2. LPS-binding affinity of RNase3, RNase6 and RN6(1–45).
Protein/Peptide LPS Binding
ED50 (µM) a Max (%) *
RNase3 2.54 ˘ 0.14 100
RNase6 2.83 ˘ 0.22 76
RN6(1–45) 5.31 ˘ 1.41 27
a ED50 values are given as mean ˘ standard error of the mean (SEM); * 100% refers to a total displacement,
whereas 0% corresponds to no displacement of the fluorescent dye, indicating no affinity for LPS.
After defining the interaction at the cell wall and membrane levels; we further characterized the
proteins and peptide ability of causing membrane disruption and cell agglutination. Therefore, LUV
containing the fluorescent probe 8-aminonaphthalene-1,3,6-trisulfonic acid/p-xylenebispyridinium
bromide (ANTS/DPX) were incubated with RNase3, RNase6 and RN6(1–45) and membrane disruption
was recorded as a function of the fluorescence increment. Both human RNases were able to totally
disrupt the ANTS/DPX LUVs at micro molar concentrations (Table 3). However, the N-terminal
derived peptide RN6(1–45) was able to produce the same effect at 2.5-fold more concentration than its
parental protein.
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Table 3. Liposome leakage activity of RNase3, RNase6 and RN6(1–45).
Protein/Peptide Liposome Leakage (µM)
ED50 (µM) a Max (%) *
RNase3 0.7 ˘ 0.1 100
RNase6 1.5 ˘ 0.5 100
RN6(1–45) 4.0 ˘ 0.5 100
a ED50 values are given as mean ˘ SEM; * 100% refers to the total leakage of liposome content.
The ANTS/DPX liposome leakage fluorescence assay was performed using DOPC/DOPG vesicles as described
in the methodology.
Additionally, dynamic light scattering (DLS) allowed us to investigate the physical changes of the
LUV population upon interaction with RNase3, RNase6 and RN6(1–45). LUVs of DOPC, DOPG and
mixture of DOPC/DOPG, with a vesicle diameter size of 100 nm, were prepared. RNase3, RNase6 and
RN6(1–45) promoted the agglutination of charged LUVs in a short time course of 15 min (Figure 2).
However, RNase6 and its N-terminal derived peptide were not able to agglutinate neutral LUVs, as
previously observed by RNase3 [39].
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2.2. Bactericidal Activity
The pro ising preli inary results on odel e branes encouraged us to further investigate
the protein and peptide mechanis of action at the bacterial cell level. Based on our previous
characterization work on the antimicrobial activity of RNase3 [38], we analyzed here the human RNase6
and its derived N-terminal peptide cytotoxic mechanism on Gra -negative and Gram-positive bacteria.
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To assess the antimicrobial activity of the human RNase3, RNase6 and its derived N-terminal
peptide RN6(1–45) we determined their minimal bactericidal concentration (MBC) against three
representative Gram-negative and Gram-positive species (Table 4).Complementarily, assessment of
the protein and peptide antimicrobial activities was also performed by evaluating the reduction of
bacterial cell viability using the BacTiter-Glo kit assay, which estimates the number of viable cells by
quantification of ATP levels (Table S1). Additionally, RNase3, RNase6 and its derived N-terminal
peptide RN6(1–45) were able to totally inhibit bacterial growth at low micro molar concentration
(Table S2). Both human RNases displayed a high antimicrobial activity in a sub micro molar range
against all tested Gram-positive and Gram-negative species. Remarkably, the N-terminal derived
peptide RN6(1–45) was able to perform the same cytotoxic effect than its parental protein.
To characterize the cell selectivity of both human RNases and the N-terminal derived peptide,
their hemolytic activity was tested on sheep RBCs, the concentration required to cause 50% hemolysis
is reported as HC50 (Table 4). The HC50 values obtained for RNase3, RNase6 and RN6(1–45) showed
that no hemolytic activity is present under the maximum concentration tested (20 µM), being at least
20- to 100-fold higher that the determined MBC values.
Table 4. Minimal bactericidal concentration (MBC100) and hemolytic activity (HC50) of RNase3, RNase6
and RN6(1–45).
Protein/Peptide MBC100 (µM) a
E. coli P. aeruginosa A. baumanii S. aureus M. luteus E. faecium HC50 (µM) *
RNase3 0.35 ˘ 0.02 0.20 ˘ 0.01 0.40 ˘ 0.03 0.40 ˘ 0.03 0.65 ˘ 0.08 0.90 ˘ 0.14 >20
RNase6 0.90 ˘ 0.14 0.90 ˘ 0.14 0.65 ˘ 0.08 1.87 ˘ 0.56 1.35 ˘ 0.23 1.35 ˘ 0.23 >20
RN6(1–45) 1.35 ˘ 0.23 0.40 ˘ 0.03 0.65 ˘ 0.08 1.87 ˘ 0.56 1.35 ˘ 0.23 1.35 ˘ 0.23 >20
a The MBC100 was calculated as described in Materials and Methods by colony forming units (CFU) counting on
plated Petri dishes. All values are averaged from three replicates of two independent experiments. Values are
given as mean ˘ SEM; * Hemolytic activity was assayed on sheep red blood cells.
Further investigations on the bactericidal properties of the human RNase6 and its derived peptide
were compared by assaying the membrane depolarization activity against two bacterial model species
(E. coli and S. aureus). As previously described [37], RNase3 is able to interact with the Gram-negative
and Gram-positive bacterial envelope, and can perturb the cell cytoplasmic membrane, producing
half of the total membrane depolarization at concentrations below 1 µM (Table 5). It is worth noticing
that comparable results were recorded for RNase6. In contrast, the antimicrobial peptide RN6(1–45)
showed a slight decrement for its ability to depolarize bacterial membranes when compared to its
parental protein.
Table 5. Depolarization activity on E.coli and S.aureus cells determined for RNase3, RNase6 and
RN6(1–45).
Protein/Peptide Depolarization (µM)
E. coli S. aureus
ED50 Depolmax * ED50 Depolmax *
RNase3 0.5 ˘ 0.1 100.5 ˘ 3.8 0.7 ˘ 0.2 100.5 ˘ 6.7
RNase6 0.6 ˘ 0.1 64.1 ˘ 4.2 0.9 ˘ 0.1 71.7 ˘ 1.5
RN6(1–45) 1.1 ˘ 0.3 69.7 ˘ 5.3 1.2 ˘ 0.2 76.2 ˘ 5.6
* Maximum fluorescence value reached at the final incubation time with 5 µM of the proteins and peptides.
Membrane depolarization was performed using the membrane potential-sensitive DiSC3(5) fluorescent probe
as described in the Methodology. Values are given as mean ˘ SEM.
In order to analyze the bactericidal kinetics of the two RNases and the RNase6 derived peptide
we used the Live/Dead bacterial viability kit. The bacterial population viability was followed by
the differential fluorescent staining of Syto 9 and propidium iodide (PI). Syto 9 can cross intact cell
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membranes, whereas PI stains damaged membrane dead cells. Therefore, the bacterial killing process
was monitored as function of time (Table 6). Human RNase6 and its derived N-terminal peptide
RN6(1–45) displayed similar bactericidal kinetics producing half of its total cytotoxic effect after several
minutes of incubation. Comparable results were also obtained for RNase3.
Additionally, further inspection of the bactericidal action at the Gram-positive and -negative cell
envelope, was applied by electron microscopy. E. coli and S. aureus were examined by transmission
electron microscopy (TEM) after 4 h of incubation with 5 µM of RNase3, RNase6 and the RN6(1–45)
peptide (Figure 3). In accordance with the results presented above, both antimicrobial RNases
and the N-terminal peptide showed a potent bactericidal effect against both E. coli and S. aureus.
Both Gram-positive and -negative cells presented a complete disruption of the cell integrity, bacterial
swelling, intracellular material spillage, bacterial cell wall layer detachment, and alteration of the
cell morphology.
Table 6. Bactericidal kinetics on E. coli and S. aureus cells determined by the Live/Dead assay for
RNase3, RNase6 and RN6(1–45).
Protein/Peptide Bacterial Viability Assay
E. coli S. aureus
t50 (min) * Viability (%) * t50 (min) * Viability (%) *
RNase3 10.6 ˘ 0.1 4.2 ˘ 0.3 7.1 ˘ 0.1 9.3 ˘ 0.2
RNase6 15.4 ˘ 0.1 8.8 ˘ 0.1 18.0 ˘ 0.4 12.9 ˘ 0.8
RN6(1–45) 13.1 ˘ 0.1 5.2 ˘ 0.1 5.5 ˘ 0.1 5.8 ˘ 0.2
* Viability percentage and half time were determined with the Live/Dead kit after 4 h of incubation of
mid-log-phase-grown E. coli and S. aureus cultures with 5 µM of protein and peptides. The percentage of
viability (%) and half time of viability (t50) after incubation with the proteins are shown. The percentage of live
bacteria was represented as a function of time, and t50 values were calculated by fitting the data to a simple
exponential decay function with Origin 7.0. Values are given as mean ˘ SEM.
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Figure 3. Transmission electron microscopy (TEM) micrographs for E. coli cultures incubated in the
absence and presence of RNase3, RNase6 and RN6(1–45). Two magnifications (upper and lower panels)
are shown for each condition to visualize the extent of bacteria aggregates and cell morphology. Scale
bars correspond to 2 µm and 500 nm, respectively.
A distinctive feature of the RNase3 mechanism of action is the ability to promote bacterial
agglutination of Gram-negative bacteria cells [41,42]. In order to assess whether RNase6 and its derived
N-terminal peptide lso shared this p rticular property, their inimal gglutination co centration
(MAC) were determined (Table 7). Strikingly, the MAC values obtai ed showed a potent agglutinating
activity for RNase6, which presented the same value as RNase3. Importantly, the N-terminal peptide
RN6(1–45) retained significant agglutinating activity, being also able to promote bacterial agglutination
at a micro molar range.
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Table 7. MAC and bacterial agglutination percentage of RNase3, RNase6 and RN6(1–45) for E. coli
cell cultures.
Protein/Peptide MAC (µM) a Agglutination Activity (%) *
RNase3 0.20 ˘ 0.05 60.35 ˘ 0.50
RNase6 0.20 ˘ 0.05 80.64 ˘ 0.50
RN6(1–45) 5 ˘ 0.50 66.22 ˘ 0.50
a E. coli cells were treated with increasing protein or peptide concentrations (from 0.01 to 20 µM); * Agglutination
activity percentage registered by incubation of bacteria culture with 5 µM protein concentration for 4 h were
calculated by Fluorescence-Activated Cell Sorting (FACS) as described in the Methodology. Values are given as
mean ˘ SEM.
Henceforth, scanning electron microscopy (SEM) was applied in order to visualize cell population
behavior and damage. SEM micrographs revealed tight densely populated bacterial aggregates after
incubation with both antimicrobial RNases and the N-terminal derived peptide (Figure 4). In addition,
cells were conspicuously damaged displaying a prominent loss of membrane integrity showing
frequent blebs and loss of the baton-shaped cell morphology.
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Finally, the agglutinating activity of the antimicrobial RNase6 and its derived N-terminal peptide
was quantified by FACS (Figure 5 and Table 7). Comparable results were obtained by both RNase3 and
6, which, after 4h incubation, were able to induce the agglutination of most of the bacterial population.
Interestingly, the antimicrobial peptide RN6(1–45) displayed a high agglutinating activity promoting
a bacterial agglutination activity similar to its parental protein.
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2.3. Mutant Design and Characterization
A closer look of the N-terminal region of RNase6 with the prediction software Aggrescan3D
showed that RNase6 presented an aggregation prone region at the first 16 residues, as reported for
RNase3 [3,40]. In order to confirm the presence of the spotted aggregation prone patch, we generated
two RNase6 mutants targeting two key residues at the identified region: Trp1 and Ile13 (Figure 1 and
Figure S1). In fact, mutation of residue 13 in both RNases sequences reduced the protein aggregation
A3D score value, defined as a global indicator of the aggregation propensity/solubility of a protein
structure. Interestingly, when we analyzed the A3D aggregation profiles we observed that while
the I13A mutation in RNase3 caused a slight reduction («20%) of the value, the same mutation in
the case of RNase6 abolished completely the aggregation propensity score (Figure S1). Structural
comparison of the aggregation regions corroborated that mutation of Ile13 decreased the aggregative
capacity of both proteins, being much more pronounced for RNase6 (Figure S1). On the other hand,
the Trp1 is fully exposed at the protein surface and may perform an equivalent role to Trp35 in RNase3.
Indeed, RNase 3-W35A mutant was found defective in its membrane interaction, lipid vesicle lysis,
agglutination and bactericidal activities [38,43–45]. Additionally, an active site mutant (H15A) was
used as a control reference, where the substitution of the His15 catalytic residue drastically impaired
the protein enzymatic activity [34].
Results confirmed the involvement of both Trp1 and Ile13 residues in RNase6 antimicrobial action.
In particular, both residues were critical for the protein cell agglutination activity (Table 8). Besides, the
results also demonstrated that the hydrophobic patch at the N-terminal region of the protein is also
related to the interaction with bacterial cell wall components. LPS binding assays for the two RNase6
mutants showed a decrease in their interaction affinities (Table 8). Moreover, both mutants displayed
a poor antimicrobial activity against E. coli and S. aureus (Table 8). On the other hand, the tested
active site mutant (H15A) retained its antimicrobial activity for both studied Gram-negative and
Gram-positive species (Table S3).
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Table 8. MBC, MAC and LPS Binding activities of RNase3, RNase6 and RNase6 mutants.
Protein/Peptide MBC100(µM) a MAC (µM) LPS Binding Assay
E. coli S. aureus E. coli S. aureus ED50 (µM) Max (%) *
RNase3 0.35 ˘ 0.01 0.40 ˘ 0.10 0.22 ˘ 0.01 >5 2.54 ˘ 0.16 99.89 ˘ 4.20
RNase6 0.90 ˘ 0.14 1.87 ˘ 0.56 0.22 ˘ 0.01 >5 2.63 ˘ 0.23 75.89 ˘ 4.41
RNase6-W1A 1.87 ˘ 0.56 3.75 ˘ 0.78 >5 >5 3.37 ˘ 0.34 38.55 ˘ 2.32
RNase6-I13A 3.75 ˘ 0.78 >5 >5 >5 4.60 ˘ 0.43 27.43 ˘ 1.22
a The MBC100 was calculated as described in Materials and Methods. MBC100 values were calculated by CFU
counting on plated Petri dishes. All values are averaged from three replicates of two independent experiments;
* 100% refers to a total displacement, whereas 0% stands for no displacement of the dye, indicating no binding.
Values are given as mean ˘ SEM.
3. Discussion
Antimicrobial RNases are small cationic proteins that belong to the vertebrate-specific RNaseA
superfamily [46]. In this study, we have thoroughly characterized the antimicrobial mechanism of
action of the human RNase6 and compared it along with the most studied human antimicrobial RNase,
RNase3 [12,21]. The present results highlight that RNase6 also displays a high antimicrobial activity
showing MBC values at sub micro molar for all tested Gram-positive and -negative bacterial species
(Table 4). Kinetic viability assays showed that the antibacterial activity occurs in a matter of few
minutes incubation time (Table 6). Furthermore, the results obtained by the fluorimetric DiSC3(5) assay
showed that RNase6 displays a high membrane depolarization activity (Table 5) indicating that one of
the main bactericidal route for these proteins takes place at the membrane level, as previously reported
for RNase3. Applying rational mutation at the RNase scaffold and peptide synthesis approaches we
have previously unveiled the main structural determinants for the antimicrobial action of human
RNase3 [37,38,41,44,45,47,48]. Specifically, we demonstrated that the entirety of the RNase3 protein
was not required for the antimicrobial action [38,44]. By applying prediction software for protein
antimicrobial regions (AMPA) and by experimental proteolysis mapping, we located the key RNase3
antimicrobial region at the N-terminus [47,49]. Interestingly, a screening of RNase7 fragments also
confirmed that the C-terminus was not able to reproduce the protein properties [27]. In fact, recent
comparative results suggested that evolution has selected the N-terminal region of the vertebrate
ribonucleases to encode the required structural determinants for antimicrobial action [3]. In the present
study, we have characterized the N-terminal region of RNase6. The corresponding RN6(1–45) peptide
displays almost the same antimicrobial activity than the whole protein; showing a fast and high
bactericidal effect mediated by the destabilization of the bacterial membranes. On the other hand,
the RNase6 also showed very low cytotoxicity levels against mammalian cells (Table 4). The results
suggest that evolution has promoted the antimicrobial properties of RNases with a high selectivity
towards pathogen cells.
Moreover, both RNase3 and 6 present the main common features of cationic antimicrobial peptides,
presenting a positive net charge that would enable them to interact with the negatively charged
bacterial cell envelopes, together with a high percentage of hydrophobic residues that could mediate
the interaction with the membrane lipid bilayer [7]. Previous structural characterization of RNase3
confirmed its mechanism of action in a membrane model system [39,43]. In tune with these facts,
internal fluorescence tryptophan spectra of the RNase6 showed how the protein is able to interact with
negatively charged membranes, as visualized by the blue-shift of the fluorescent emission wavelength
(Table 1). Additionally, the structural determinants required for membrane interaction were retained
by the N-terminal region, as a significant blue-shift was also registered for the RNase6 derived peptide.
On the other hand, the results indicated that RNase6 is able to interact with the negatively charged
LPS molecules of the Gram-negative surface (Table 2), serving as the first point of anchor to exert
the membranolytic activity. Also, the ANTS/DPX fluorescence assay showed that RNase6 is able
to destabilize lipid bilayers very efficiently, presenting a high membrane lysis at low micro molar
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concentrations (Table 3). Our previous work identified a key antimicrobial region for RNase3 (residues
24 to 45) essential for membrane leakage, depolarization and LPS binding [47]. Moreover, recent
comparative analysis of human RNases N-terminus peptides confirmed their structuration, adopting
a secondary helical conformation, in the presence of sodium dodecyl sulfate (SDS) and LPS micelles [3].
Interestingly, we have proven here that the N-terminal region of the homologue RNase6 is also able
to reproduce the membrane destabilization properties of the whole protein. Nonetheless, significant
differences between the two proteins were observed regarding the LPS binding activity; where the
RNase6 N-terminal region shows reduced LPS binding. Differences at the predicted protein LPS
binding residues may account for this data [3,42].
Another important feature for RNase3 antimicrobial activity is the ability to agglutinate
Gram-negative bacterial cells in a LPS binding dependent manner [42]. We previously demonstrated
that RNase3 upon interaction with the negatively charged surfaces of the bacteria underwent
conformational changes that triggered the amyloid-like self-aggregation of the protein ensuing in
bacterial agglutination and eventual cell death [19,40]. Antimicrobial peptides endowed with a cell
agglutinating activity would prevent dissemination of the infectious focus and facilitate the infection
clearance by the host innate cells [19,50]. Interestingly, RNase6 is also able to aggregate both lipid
vesicles and Gram-negative bacteria in a micro molar range. Electron micrographs not only showed the
evident cell damage that RNase6 antimicrobial action produces but they also revealed densely packed
bacterial aggregates, as observed for RNase3 [37]. Quantification of the agglutinating activity of the
RNase6 by FACS showed that the totality of the bacterial population is agglutinated at 5 µM protein
concentration (Figure 5). Again, the N-terminal region of RNase6 retained the agglutinating properties
of the whole protein (Table 7). To confirm this hypothesis, two point mutants were designed at the
spotted aggregation propensity region (W1A and I13A). The results confirmed that substitution of
both hydrophobic residues reduced considerably the bacterial agglutination activity and antimicrobial
action (Table 8). Significant reduction of the protein LPS interaction was also obtained for both mutant
variants (Table 8). Interestingly, Trp1 is unique to RNase6 lineage and is conserved in all the sequenced
Old World primate genes [51–53]. On the other hand, previous studies from our laboratory highlighted
the involvement of Ile13 in the RNase3 agglutination properties [40,45]. Moreover, the residue is
present in the three main antimicrobial RNases within the family (Figure 1). Comparison of the
8 N-terminal peptides from the human canonical RNases confirmed the direct correlation between
the hydrophobic patch and the protein agglutination and bactericidal properties [3]. Besides, no
reduction of the RNase6 antimicrobial activity was observed for the H15A active site mutant (Table S3).
Therefore, our present results are confirming that residues Trp1 and Ile13 play a crucial role in RNase6
bacterial cell surface interaction, membrane disruption and bacterial agglutination.
4. Materials and Methods
4.1. Materials and Strains
DOPC and DOPG were from Avanti Polar Lipids (Alabaster, AL, USA). ANTS, DPX and BC
were purchased from Invitrogen (Carlsbad, CA, USA). LPS from E. coli serotype 0111:B4 were
purchased from Sigma-Aldrich (St. Louis, MO, USA). PD-10 desalting columns with Sephadex
G-25 were from GE Healthcare (Waukesha, WI, USA). RNase6(1–45) peptide was purchased from
Genecust (Dudelange, Luxembourg). Strains used were Escherichia coli (BL21; Novagen, Madison, WI,
USA), Staphylococcus aureus (ATCC 502A; Manassas, VA, USA), Acinetobacter baumannii (ATCC 15308;
Manassas, VA, USA), Pseudomonas aeruginosa (ATCC 47085; Manassas, VA, USA), Micrococcus luteus
(ATCC 7468; Manassas, VA, USA) and Enterococcus faecium (ATCC 19434; Manassas, VA, USA).
4.2. Protein Expression and Purification
Wild-type RNase3 was obtained from a synthetic gene [54]. Human RNase6 was obtained
from DNA 2.0 (Menlo Park, CA, USA). Both genes were subsequently cloned into pET11c vectors.
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Mutations into the RNase6 gene were introduced using the Quick change™ site-directed mutagenesis
kit (Santa Clara, CA, USA) following the manufacturers procedure. E. coli BL21(DE3) (Novagen,
Madison, WI, USA) competent cells were transformed with the pET11c/RNase6 and RNase3 plasmids.
The expression protocol was optimized in Terrific broth (TB). For high yield expression, bacteria
were grown in TB, containing 400 µg/mL ampicillin. Recombinant RNase6 was expressed in E. coli
BL21(DE3) (Novagen, Madison, WI, USA) cells after induction with 1 mM IPTG (St. Louis, MO, USA),
added when the culture showed an OD600 of 0.6. The cell pellet was collected after 4 h of culture at
37 ˝C. Cells were resuspended in 10 mM Tris-HCl, 2 mM EDTA, pH 8, and sonicated at 50 watts for
10 min with 30-s cycles. After centrifugation at 15,000ˆ g for 30 min, the pellet fraction containing
inclusion bodies was processed as follows: the pellet fraction was washed with 50 mM Tris-HCl, 2 mM
EDTA, 0.3 M NaCl, pH 8, and after centrifugation at 20,000ˆ g for 30 min, the pellet was dissolved
in 12 mL of 6 M guanidine HCl, 0.1 M Tris-acetate, 2 mM EDTA, pH 8.5, containing 80 mM GSH
(St. Louis, MO, USA), and incubated under nitrogen for 2 h at room temperature. The protein was
then refolded by a rapid 100-fold dilution into 0.1 M Tris-HCl, pH 7.5, containing 0.5 M L-arginine,
and GSSG (St. Louis, MO, USA) was added to obtain a GSH/GSSG ratio of 4. Dilution in the refolding
buffer was adjusted to obtain a final protein concentration of 30–150 µg/mL. The protein was incubated
in refolding buffer for 48–72 h at 4 ˝C. The folded protein was then concentrated, dialyzed against
0.015 M Tris-HCl, pH 7, and purified by cation exchange chromatography on a Resource S column
equilibrated with the same buffer. ECP was eluted with a linear NaCl gradient from 0 to 2 M in 0.015 M
Tris-HCl, pH 7 buffer. Further purification was achieved by a second reverse phase chromatography on
a Vydac C4 column (Grace-Alltech, Bannockburn, IL, USA). The homogeneity of the purified proteins
was checked by 15% SDS-PAGE and Coomassie Blue staining and by N-terminal sequencing.
4.3. Minimal Bactericidal Concentration (MBC)
Antimicrobial activity was expressed as the MBC100, defined as the lowest protein concentration
that completely kills a microbial population. The MBC of each protein/peptide was determined
from two independent experiments performed in triplicate for each concentration. Bacteria cells
were incubated at 37 ˝C overnight in LB broth and diluted to give approximately 5 ˆ 105 CFU
(colony forming units)/mL. The bacterial suspension was incubated in LB with peptides at various
concentrations (0.1–20 µM) at 37 ˝C for 4 h. Samples were plated on to Petri dishes and incubated at
37 ˝C overnight.
4.4. Bacterial Viability Assays
Kinetics of bacterial survival were determined using the Live/Dead bacterial viability kit
(Molecular Probes, Invitrogen) in accordance with the manufacturer’s instructions. Bacterial strains
were grown at 37 ˝C to an optical density (OD600) of 0.2, centrifuged at 5000ˆ g for 5 min, and stained
in a 0.85% NaCl solution. Fluorescence intensity was continuously measured after protein or peptide
addition (10 µM) using a Cary Eclipse spectrofluorimeter (Varian Inc., Palo Alto, CA, USA). To calculate
bacterial viability, the signal in the range of 510 to 540 nm was integrated to obtain the Syto 9 signal
(live bacteria) and that in the range of 620 to 650 nm was integrated to obtain the propidium iodide
(PI) signal (dead bacteria). The percentage of live bacteria was represented as a function of time, and
t50 values were calculated by fitting the data to a simple exponential decay function with Origin 7.0
(OriginLab Corporation; Northampton, MA, USA).
Alternatively, bacterial viability was assayed using the BacTiter-Glo microbial cell viability kit
(Promega; Fitchburg, WI, USA) that estimates the number of viable cells by ATP quantification using
a fluorescence assay. Briefly, proteins and peptides were dissolved in 10 mM sodium phosphate
buffer, 0.1 M NaCl (pH 7.4), serially diluted from 20 to 0.1 µM, and tested against the bacterial
species (OD600 ~ 0.2) for 4 h of incubation time. Fifty microliters of culture were mixed with 50 µL of
BacTiter-Glo reagent in a microtiter plate according to the manufacturer’s instructions and incubated
at room temperature for 15 min. Luminescence were read on a Victor3 plate reader (Perkin-Elmer,
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Waltham, MA, USA) with a 3-s integration time. Fifty percent effective dose concentrations (ED50)
were calculated by fitting the data to a dose–response curve with Origin 7.0.
4.5. Bacterial Cell Membrane Depolarization Assay
Membrane depolarization was performed using the membrane potential-sensitive DiSC3(5)
fluorescent probe as described previously [41,55]. After interaction with intact cytoplasmic membrane,
the fluorescent probe DiSC3(5) was quenched. After incubation with the antimicrobial protein or
peptide, the membrane depolarization was induced the probe was released to the medium, ensuing
in an increase of fluorescence that can be quantified and monitored as a function of time. Bacterial
cultures were grown at 37 ˝C to an OD600 of 0.2, centrifuged at 5.000ˆ g for 7 min, washed with 5 mM
HEPES-KOH, 20 mM glucose (pH 7.2), and resuspended in 5 mM HEPES-KOH 20 mM glucose 100 mM
KCl (pH 7.2) to an OD600 of 0.05. DiSC3(5) was added to a final concentration of 0.4 µM, and changes
in the fluorescence were continuously recorded after the addition of protein (from 0.01 to 20 µM) in
a Victor3 plate reader. Effective dose values (ED50) were estimated from nonlinear regression analysis.
4.6. Minimal Agglutination Activity (MAC)
Bacterial cells were grown at 37 ˝C to an OD600 of 0.2, centrifuged at 5000ˆ g for 2 min.
One hundred microliters of the bacterial suspension was treated with increasing protein or peptide
concentrations (from 0.01 to 20 µM) and incubated at 37 ˝C for 1 h. The aggregation behavior
was observed by visual inspection, and the agglutinating activity is expressed as the minimum
agglutinating concentration of the sample tested, as previously described [42].
4.7. Fluorescence Activated Cell-Sorting (FACS)
Bacterial cells were grown at 37 ˝C to mid-exponential phase (OD600 of 0.6), centrifuged at 5000ˆ g
for 2 min, resuspended in 10 mM sodium phosphate buffer and 100 mM NaCl (pH 7.4) to give a final
OD600 of 0.2 and pre-incubated for 20 min. A 500-µL aliquot of the bacterial suspension was incubated
with 5 µM protein/peptide for 4 h. After incubation, 25,000 cells were subjected to FACS analysis using
a FACS Calibur cytometer (BD Biosciences; Franklin Lakes, NJ, USA) and a dot-plot was generated by
representing the low-angle forward scattering (FSC-H) in the x-axis and the side scattering (SSC-H) in
the y-axis to analyze the size and complexity of the cell cultures.
4.8. Scanning Electron Microscopy (SEM)
Scanning electron microscopy (SEM) samples were prepared as previously described [56].
Bacterial culture of S. aureus and E. coli were grown at 37 ˝C to mid-exponential phase (OD600 of 0.2)
and incubated with proteins or peptide (5 µM) at 37 ˝C. Sample aliquots (500 µL) were taken after up
to 4 h of incubation and prepared for SEM analysis as previously described [41]. The micrographs were
viewed at a 15-kV accelerating voltage on a Hitachi S-570 scanning electron microscope (Hitachi, Ltd.;
Chiyoda, Tokio, Japan), and a secondary electron image of the cells for topography contrast was
collected at several magnifications.
4.9. Transmission Electron Microscopy
Transmission electron microscopy (TEM) samples were prepared as previously described [56].
E. coli and S. aureus cultures were grown to an OD600 of 0.2 and incubated at 37 ˝C with 5 µM proteins
or peptides for 4 h. After treatment, bacterial pellets were prefixed with 2.5% glutaraldehyde and
2% paraformaldehyde in 0.1 M cacodylate buffer at pH 7.4 for 2 h at 4 ˝C and postfixed in 1% osmium
tetroxide buffered in 0.1 M cacodylate at pH 7.4 for 2 h at 4 ˝C. The samples were dehydrated in
acetone (50%, 70%, 90%, 95%, and 100%). The cells were immersed in Epon resin, and ultrathin sections
were examined in a JEOL JEM 2011 instrument (JEOL, Ltd., Tokyo, Japan).
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4.10. Hemolytic Activity
Fresh sheep RBCs (red blood cells) (Oxoid Inc.; Nepean, ON, Canada) were washed three times
with PBS (35 mM phosphate buffer and 0.15 M NaCl (pH 7.4)) by centrifugation for 5 min at 3000ˆ g
and resuspended in PBS at 2 ˆ 107 cells/mL. RBCs were incubated with protein/peptide at 37 ˝C
for 4 h and centrifuged at 13,000ˆ g for 5 min. The supernatant was separated from the pellet and
its absorbance measured at 570 nm. The 100% hemolysis was defined as the absorbance obtained
by sonicating RBCs for 10 s. HC50 was calculated by fitting the data to a sigmoidal function with
Origin 7.0.
4.11. Liposome Preparation
Large Unilamellar Vesicles (LUVs) containing DOPC, DOPG or DOPC/DOPG (3:2 molar ratio) of
a defined size were obtained from a vacuum drying lipid chloroform solution by extrusion through
100 nm polycarbonate membranes. The lipid suspension was frozen and thawed ten times before
extrusion. A 1 mM stock solution of liposome suspension was prepared in 10 mM sodium phosphate,
100 mM NaCl, pH 7.4.
4.12. Intrinsic Tryptophan Fluorescence Analysis
Tryptophan fluorescence emission spectra were recorded using a 280 nm excitation wavelength.
Slits were set at 2 nm for excitation and 5–10 nm for emission. Emission spectra were recorded
from 300–400 nm at a scan rate of 60 nm/min in a 10 mm ˆ 10 mm cuvette, with stirring
immediately after sample mixing. Protein/peptide spectra at 0.5 µM in 10 mM Hepes buffer, pH 7.4,
were obtained at 37 ˝C in the absence or presence of 200 µM liposome suspension or 100 µM
LPS micelles. Fluorescence measurements were performed on a Cary Eclipse spectrofluorimeter
(Agilent Technologies, Bath, UK). Spectra in the presence of liposomes or LPS were corrected for
light scattering by subtracting the corresponding background. For each condition three spectra was
averaged. The maximum of the fluorescence spectra was calculated fitting the data to a log-normal
distribution function with Origin 7.0.
4.13. Liposome Leakage
The ANTS/DPX liposome leakage fluorescence assay was performed as previously described [43].
Briefly, a unique population of LUVs DOPC/DOPG (3:2) was prepared to encapsulate a solution
containing 12.5 mM ANTS, 45 mM DPX, 20 mM NaCl, and 10 mM Tris/HCl, pH 7.5. The ANTS/DPX
liposome stock suspension was diluted to 30 µM and incubated at 37 ˝C with protein/peptide, serially
diluted from 20 to 0.1 µM in a microtiter plate. Fluorescence measurements were performed on
a Victor3 plate reader (PerkinElmer, Waltham, MA, USA). ED50 values were calculated by fitting the
data to a dose–response curve with Origin 7.0.
4.14. Liposome Aggregation
Liposome aggregation was assessed by Dynamic Light Scattering (DLS). A unique population of
LUVs DOPC, DOPG or DOPC/DOPG was incubated at 37 ˝C with 5 µM of each protein/peptide for
15 min. Particle size distribution was measured with a Zetasizer Nano ZS (Malvern Instruments Ltd.,
Worcestershire, UK). Polydispersity of LUV population was also analyzed. Size radius was plotted
versus protein concentration.
4.15. LPS Binding Fluorimetric Assay
Protein binding to LPS was assessed using the fluorescent probe BODIPY® cadaverine (BC)
(St. Louis, MO, USA). BC binds strongly to native LPSs, specifically recognizing the lipid A portion.
When a protein that interacts with LPSs is added, the BC is displaced from the complex, and its
fluorescence is increased. LPS-binding assays were carried out in 10 mM Hepes buffer at pH 7.2.
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The displacement assay was performed by a microtiter plate containing a stirred mixture of either
LPS (10 µg/mL) and BC (10 µM). Proteins and peptide were serially diluted from 20 to 0.1 µM.
Fluorescence measurements were performed on a Victor3 plate reader (PerkinElmer, Waltham,
MA, USA).
4.16. Aggrescan3D Analysis
Aggregation propensity of RNase6 was calculated by Aggrescan3D server [57]. The A3D value
was calculated for each protein residue as described. The analysis was performed with the dynamic
mode enabled and the distance of aggregation analysis was defined to 10 Å.
4.17. Minimal Inhibitory Concentration (MIC)
Minimal inhibitory concentration expressed as MIC100, defined as the lowest protein concentration
that completely inhibits microbial growth. The MIC of each protein/peptide was determined from
two independent experiments performed in duplicate for each concentration. Bacteria cells were
incubated at 37 ˝C overnight in LB broth and diluted to give approximately 5 ˆ 105 CFU (colony
forming units)/mL. The bacterial suspension was incubated in LB with peptides at serially diluted
concentrations (0.1–20 µM) at 37 ˝C for 20 h. Bacterial growth inhibition was determined by measuring
the optical density (OD) of the samples at a wavelength of 570 nm.
5. Conclusions
In this work, we have characterized for the first time the bactericidal properties of the human
RNase6. Our data suggest that the antimicrobial mechanism of action encompasses two steps:
the protein firstly interacts with the negatively charged envelopes of the bacterial cell, promptly
followed by a combination of membrane destabilization and bacterial agglutination. Furthermore, the
N-terminal domain of the protein was proven to retain the antimicrobial properties of the whole
protein; encouraging us to use the scaffold of the human RNase6 for the future development of new
peptide based antimicrobial agents.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/
17/4/552/s1.
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